secwatch.observer — SEC 8-K summary
======================================

Issuer:     JOHNSON & JOHNSON (JNJ)
CIK:        0000200406
Form:       8-K
Filed at:   2026-01-21T23:59:59+00:00
Accession:  0000200406-26-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46
--------------------------------------------------------------------------------

- Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).
- Q4 net earnings $5,116M ($2.10 diluted EPS) vs $3,431M ($1.41) a year ago.
- Adjusted Q4 net earnings $6,009M ($2.46 adj. diluted EPS) vs $4,946M ($2.04).
- R&D expense decreased 19.7% YoY to $4,252M; effective tax rate was -3.0%.
- MedTech segment sales $8,801M (+7.5% YoY); Innovative Medicine $15,763M (+10.0% YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/0000200406-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/jnj-20260121.htm
  HTML page:      https://secwatch.observer/filing/0000200406-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer